Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 13/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3428572 | 0.96 | F10 (0.47) | F10MAPK14MEN1ALDH1A1MAPT | |
| SCHEMBL3425883 | 0.91 | F10 (0.39) | F10MAPK14MEN1MAPTHTT | |
| SCHEMBL3428575 | 0.89 | F10 (0.48) | F10MAPK14 | |
| SCHEMBL3426826 | 0.88 | MAPK14 (0.40) | F10MAPK14MEN1ALDH1A1MAPT | |
| SCHEMBL3428698 | 0.87 | MAPK14 (0.38) | F10MAPK14MEN1ALDH1A1MAPT | |
| SCHEMBL3421824 | 0.85 | F10 (0.53) | F10MEN1ALDH1A1MAPTHTT | |
| SCHEMBL3429300 | 0.83 | F10 (0.51) | F10MEN1ALDH1A1MAPTHTT | |
| SCHEMBL3425541 | 0.81 | MAPK14 (0.39) | F10MAPK14MEN1MAPTHTT | |
| SCHEMBL3428639 | 0.80 | F10 (0.47) | F10MAPK14ALDH1A1KDM4ENPSR1 | |
| SCHEMBL3426427 | 0.80 | MAPK14 (0.39) | F10MAPK14MEN1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732466-B2 | Substituted thiophene carboxamides, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-08 | — | — | US | disclosed |
| US-20060293300-A1 | New substituted thiophene carboxamides, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293300-A1 | New substituted thiophene carboxamides, process for their preparation and their use as medicaments | OTC, TPMT, ABCG2 | F10 1901/4885MAPK14 3431/4885MEN1 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.